仙琚制药12月19日获融资买入568.68万元，融资余额4.92亿元

Group 1 - The core viewpoint of the news is that Xianju Pharmaceutical has experienced fluctuations in financing and stock performance, with significant changes in both revenue and net profit year-on-year [1][2]. - As of December 19, Xianju Pharmaceutical's stock price increased by 0.99%, with a trading volume of 79.39 million yuan. The financing buy-in amount was 5.69 million yuan, while the financing repayment was 12.40 million yuan, resulting in a net financing buy-in of -6.71 million yuan [1]. - The total balance of margin trading for Xianju Pharmaceutical reached 494 million yuan, with the financing balance accounting for 5.41% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of November 30, the number of shareholders for Xianju Pharmaceutical was 50,000, a decrease of 1.96% from the previous period, while the average circulating shares per person increased by 2.00% to 19,691 shares [2]. - For the period from January to September 2025, Xianju Pharmaceutical reported an operating income of 2.826 billion yuan, a year-on-year decrease of 12.71%, and a net profit attributable to the parent company of 407 million yuan, down 23.29% year-on-year [2]. - Since its A-share listing, Xianju Pharmaceutical has distributed a total of 2.031 billion yuan in dividends, with 989 million yuan distributed over the past three years [3].